Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for
end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a
treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side
effects.
In this pilot study patients with membranous nephropathy and renal failure will be treated
with mycophenolate mofetil and prednisone. The outcome will be compared with historical
controls treated with a similar regimen containing cyclophosphamide.